Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

bezlotoxumab

bezlotoxumab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Zinplava SOLUTION, INTRAVENOUS 1,000 mg/40 mL (25 mg/mL)        
Comments:

Discontinued by manufacturer (Merck) January 31, 2025 and is no longer available in the United States.

 

Contact to discuss and interchange to IVIG in both inpatient and outpatient setting. INTERCHANGE IS NOT AUTOMATIC. Physician may decide on an alternative therapy.

Order Formulation Therapeutic Interchange

bezlotoxumab (Zinplava)

  • 10 mg/kg

immune globulin intravenous (Gamunex)

  • 400 mg/kg (Not Automatic)

 

Reviewed: 26 Sept 2017 (Zinplava), 28 April 2020

Updated: July 2025 (Permanent Discontinuation)

Last updated: Jul. 2, 2025
Cost: ewe






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2025 Rpharmy, LLC ­ All Rights Reserved